Background The biomarker model of Alzheimer's disease postulates a dynamic sequence of
amyloidosis, neurodegeneration, and cognitive decline as an individual progresses from …

Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly
from a preclinical phase into a fully expressed clinical syndrome. We aimed to use …

Background Insights gained from studying individuals with autosomal dominant Alzheimer's
disease have broadly influenced mechanistic hypotheses, biomarker development, and …

Summary Background Models of Alzheimer's disease propose a sequence of amyloid β (Aβ)
accumulation, hypometabolism, and structural decline that precedes the onset of clinical …

Background Improved understanding is needed of risk factors and markers of disease
progression in preclinical Alzheimer's disease. We assessed associations between brain β …

Background The causes of phenotypic heterogeneity in familial Alzheimer's disease with
autosomal dominant inheritance are not well understood. We aimed to characterise clinical …

Background In a 2014 cross-sectional analysis, we showed that amyloid and
neurodegeneration biomarker states in participants with no clinical impairment varied …

Objective: To investigate the associations of cerebral amyloidosis with concurrent cognitive
performance and with longitudinal cognitive decline in asymptomatic and symptomatic …

Summary Background As preclinical Alzheimer's disease becomes a target for therapeutic
intervention, the overlap between imaging abnormalities associated with typical ageing and …

Background New research criteria for preclinical Alzheimer's disease have been proposed,
which include stages for cognitively normal individuals with abnormal amyloid markers …